Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Molecules ; 18(4): 4209-20, 2013 Apr 10.
Artigo em Inglês | MEDLINE | ID: mdl-23612473

RESUMO

Previous studies have shown that systemic administration of 6'-hydroxy-2',4'-dimethoxychalcone (flavokawin B, FKB) exerts significant peripheral and central antinociceptive effects in laboratory animals. However, the mechanisms underlying these peripheral and central antinociceptive effects have yet to be elucidated. Therefore, the objective of the present study was to evaluate the participation of nitric oxide (NO)/cyclic guanosine monophosphate (cGMP)/potassium (K+) channels pathway in the peripheral antinociception induced by FKB. It was demonstrated that intraplantar (i.pl.) administration of FKB (150, 250, 375 and 500 µg/paw) resulted in dose-dependent peripheral antinociception against mechanical hyperalgesia in carrageenan-induced hyperalgesia test model in rats. The possibility of FKB having either a central or a systemic effect was excluded since administration of FKB into the right paw did not elicit antinociception in the contralateral paw. Furthermore, peripheral antinociception induced by FKB (500 µg/paw) was significantly reduced when L-arginine (25 µg/paw, i.pl.), Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; 50 µg/paw, i.pl.), glibenclamide (300 µg/paw, i.pl.), tetraethylammonium (300 µg/paw, i.pl.) and charybdotoxin (3 µg/paw, i.pl.) were injected before treatment. Taken together, our present data suggest that FKB elicits peripheral antinociception when assessed in the mechanical hyperalgesia induced by carrageenan. In addition, it was also demonstrated that this effect was mediated through interaction of the NO/cGMP/K+ channels signaling pathway.


Assuntos
Analgésicos/farmacologia , Chalcona/farmacologia , GMP Cíclico/metabolismo , Flavonoides/farmacologia , Óxido Nítrico/metabolismo , Canais de Potássio/metabolismo , Transdução de Sinais/efeitos dos fármacos , Analgésicos/administração & dosagem , Animais , Arginina/administração & dosagem , Arginina/farmacologia , Carragenina/efeitos adversos , Chalcona/administração & dosagem , Modelos Animais de Doenças , Flavonoides/administração & dosagem , Hiperalgesia/induzido quimicamente , Hiperalgesia/tratamento farmacológico , Hiperalgesia/metabolismo , Masculino , Bloqueadores dos Canais de Potássio/administração & dosagem , Bloqueadores dos Canais de Potássio/farmacologia , Ratos
2.
Basic Clin Pharmacol Toxicol ; 108(3): 155-62, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-20955360

RESUMO

This study investigated the antinociceptive effects of zerumbone in chemical behavioural models of nociception in mice. Zerumbone given through intraperitoneal route (i.p.) produced dose-related antinociception when assessed on acetic acid-induced abdominal writhing test in mice. In addition, the i.p. administration of zerumbone exhibited significant inhibition of the neurogenic pain induced by intraplantar (i.pl.) injection of capsaicin and bradykinin. Likewise, zerumbone given by i.p. route reduced the nociception produced by i.pl. injection of glutamate and phorbol myristate acetate (PMA). The antinociception caused by zerumbone in the acetic acid test was significantly attenuated by i.p. pre-treatment of mice with l-arginine (nitric oxide precursor) and glibenclamide (ATP-sensitive K(+) channel inhibitor). However, the antinociception of zerumbone was enhanced by methylene blue (non-specific gyanylyl cyclase inhibitor). Together, these results indicate that zerumbone produces pronounced antinociception against chemical models of nociception in mice. It also strongly suggests that the l-arginine-nitric oxide-cGMP-PKC-K(+) ATP channel pathways, the TRPV1 and kinin B2 receptors play an important role in the zerumbone-induced antinociception.


Assuntos
Analgésicos/uso terapêutico , Arginina/metabolismo , GMP Cíclico/metabolismo , Canais KATP/metabolismo , Óxido Nítrico/metabolismo , Proteína Quinase C/metabolismo , Sesquiterpenos/uso terapêutico , Analgésicos/farmacologia , Animais , Comportamento Animal/efeitos dos fármacos , GMP Cíclico/antagonistas & inibidores , Relação Dose-Resposta a Droga , Ativação Enzimática/efeitos dos fármacos , Canais KATP/antagonistas & inibidores , Masculino , Camundongos , Camundongos Endogâmicos ICR , Atividade Motora/efeitos dos fármacos , Óxido Nítrico/antagonistas & inibidores , Medição da Dor , Bloqueadores dos Canais de Potássio/farmacologia , Receptor B2 da Bradicinina/agonistas , Receptor B2 da Bradicinina/metabolismo , Sesquiterpenos/farmacologia , Canais de Cátion TRPV/antagonistas & inibidores , Canais de Cátion TRPV/metabolismo , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...